US2010316598A1PendingUtilityA1
Methods of treating cancer using il-21
Est. expiryJun 7, 2022(expired)· nominal 20-yr term from priority
A61P 37/04A61P 9/00A61P 35/04A61P 37/02A61P 31/12A61P 35/00A61P 33/02A61P 31/16A61P 35/02A61P 31/06A61P 31/14A61P 31/22A61P 31/04A61P 31/00A61P 31/10A61P 31/18A61P 31/20A61P 25/00A61P 1/00A61P 19/02A61P 1/04A61P 11/00A61P 1/16A61K 38/20A61K 38/2026A61K 38/2086A61K 38/193C07K 16/2878A61K 38/2013A61K 45/06C07K 14/54C07K 2317/73Y02A50/30
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for treating mammals with cancer using molecules that have an IL-21 functional activity are described. The molecules having IL-21 functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer therapeutics.
Claims
exact text as granted — not AI-modified1 . A method of treating cancer comprising administering to a subject having Non-Hodgkin's lymphoma in need thereof a therapeutically effective amount of an IL-21 polypeptide comprising residues 32 (Gln) to 162 (Ser) of SEQ ID NO:2 in combination with monoclonal antibody therapy, wherein the monoclonal antibody is an anti-CD20 antibody.
2 . The method of claim 1 , wherein a tumor response is measured as complete response, partial response, prolonged survival or reduction of measurable disease.
3 . The method of claim 1 , wherein the monoclonal antibody therapy is RITUXANT™.
4 . The method of claim 1 , wherein there is a tumor response.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.